Published in Haemophilia on July 01, 2001
A safe and reliable method of intra-operative limb positioning. Ann R Coll Surg Engl (2001) 0.75
von Willebrand factor-cleaving protease in thrombotic thrombocytopenic purpura and the hemolytic-uremic syndrome. N Engl J Med (1998) 6.17
Transmission of hepatitis C with pasteurised factor VIII. Lancet (1992) 2.62
Congenital deficiency of vitamin K dependent coagulation factors in two families presents as a genetic defect of the vitamin K-epoxide-reductase-complex. Thromb Haemost (2000) 2.34
Elevated fibrinogen and plasminogen activator inhibitor (PAI-1) in hypertension are related to metabolic risk factors for cardiovascular disease. J Intern Med (1990) 2.25
New early prophylaxis regimen that avoids immunological danger signals can reduce FVIII inhibitor development. Haemophilia (2009) 2.01
The comparison of the efficacy and safety of intravenous versus subcutaneous immunoglobulin replacement therapy. J Clin Immunol (2000) 2.01
Demographic and clinical data in acquired hemophilia A: results from the European Acquired Haemophilia Registry (EACH2). J Thromb Haemost (2012) 1.74
Hemorrhagic symptoms and bleeding risk in obligatory carriers of type 3 von Willebrand disease: an international, multicenter study. J Thromb Haemost (2006) 1.70
Deep vein thrombosis of the axillary-subclavian veins: epidemiologic data, effects of different types of treatment and late sequelae. Eur J Vasc Surg (1988) 1.53
Characterization of inhibitors to FVIII with an ELISA in congenital and acquired haemophilia A. Haemophilia (2002) 1.42
[A complication in Budd-Chiari syndrome. Heparin therapy caused thrombocytopenia]. Lakartidningen (1994) 1.39
Factor IX inhibitors and anaphylaxis in hemophilia B. J Pediatr Hematol Oncol (1997) 1.34
Primary prophylaxis in severe haemophilia should be started at an early age but can be individualized. Br J Haematol (1999) 1.32
Treating insulin resistance in hypertension with metformin reduces both blood pressure and metabolic risk factors. J Intern Med (1991) 1.30
X-linked inhibitor of apoptosis (XIAP) deficiency: the spectrum of presenting manifestations beyond hemophagocytic lymphohistiocytosis. Clin Immunol (2013) 1.26
Hemostatic and metabolic variables in women with polycystic ovary syndrome. Fertil Steril (1994) 1.22
Two different mechanisms in patients with venous thrombosis and defective fibrinolysis: low concentration of plasminogen activator or increased concentration of plasminogen activator inhibitor. Br Med J (Clin Res Ed) (1985) 1.19
A randomized, controlled trial to study the efficacy and safety of C1 inhibitor concentrate in treating hereditary angioedema. Transfusion (1998) 1.15
Distal 2q duplication: report of two familial cases and an attempt to define a syndrome. Am J Med Genet (1979) 1.13
Chitin-based scaffolds are an integral part of the skeleton of the marine demosponge Ianthella basta. J Struct Biol (2009) 1.12
Abdominal obesity is associated with an impaired fibrinolytic activity and elevated plasminogen activator inhibitor-1. Metabolism (1990) 1.12
Blood transfusion. Iron load and retinopathy of prematurity. Eur J Pediatr (1997) 1.11
Consensus perspectives on prophylactic therapy for haemophilia: summary statement. Haemophilia (2003) 1.10
Hemophilia joint health score reliability study. Haemophilia (2006) 1.09
Rapid subcutaneous immunoglobulin administration every second week results in high and stable serum immunoglobulin G levels in patients with primary antibody deficiencies. Clin Exp Immunol (2008) 1.02
Treatment of haemophilia A and B and von Willebrand's disease: summary and conclusions of a systematic review as part of a Swedish health-technology assessment. Haemophilia (2011) 1.01
A patient with Glanzmann thrombasthenia and epistaxis successfully treated with recombinant factor VIIa. Thromb Haemost (1996) 1.01
Serum levels of insulin-like growth factor-I, -II and insulin-like growth factor binding proteins -2 and -3 in children with acute lymphoblastic leukaemia. Eur J Pediatr (1996) 1.01
Normal vaginal delivery is to be recommended for haemophilia carrier gravidae. Acta Paediatr (1994) 1.01
Diagnostic symptoms of severe and moderate haemophilia A and B. A survey of 140 cases. Acta Paediatr Scand (1990) 1.00
von Willebrand factor antigen and plasminogen activator inhibitor in giant cell arteritis. Ann Rheum Dis (1991) 0.99
Electron holography of biological samples. Micron (2007) 0.99
Complex functional and structural coagulation abnormalities in the carbohydrate-deficient glycoprotein syndrome type I. Blood Coagul Fibrinolysis (1996) 0.99
Monoclonal antibody defines CA 19-9 in pancreatic juices and sera. Gut (1985) 0.98
Pregnancy in women with congenital antithrombin III deficiency: experience of treatment with heparin and antithrombin. Gynecol Obstet Invest (1982) 0.97
Use of recombinant factor VIIa (NovoSeven) in patients with Glanzmann thrombasthenia. Semin Hematol (2001) 0.96
Haemophilia B mutations in Sweden: a population-based study of mutational heterogeneity. Br J Haematol (2001) 0.96
High fibrinogen and plasminogen activator inhibitor activity in growth hormone-deficient adults. Arterioscler Thromb (1994) 0.96
Silencing or knocking out eukaryotic gene expression by oligodeoxynucleotide decoys. Crit Rev Eukaryot Gene Expr (2006) 0.96
Prevalence of factor V Leiden in children with thrombo-embolism. Eur J Pediatr (1996) 0.94
Recombinant, B-domain deleted factor VIII (r-VIII SQ): pharmacokinetics and initial safety aspects in hemophilia A patients. Thromb Haemost (1997) 0.93
Costs of on-demand and prophylactic treatment for severe haemophilia in Norway and Sweden. Haemophilia (2004) 0.93
Changes of plasma coagulation and fibrinolysis in response to mental stress. Thromb Haemost (1989) 0.91
Synergistic effects of oxidative environments and mechanical stress on in vitro stability of polyetherurethanes and polycarbonateurethanes. J Biomed Mater Res (1999) 0.90
Recent developments in clinimetric instruments. Haemophilia (2006) 0.89
von Willebrand's disease: a report from a meeting in the Åland islands. Haemophilia (2012) 0.89
Chemical stability of polyether urethanes versus polycarbonate urethanes. J Biomed Mater Res (1997) 0.89
Four novel mutations in deficiency of coagulation factor XIII: consequences to expression and structure of the A-subunit. Blood (1996) 0.89
Recombinant ADAMTS13 normalizes von Willebrand factor-cleaving activity in plasma of acquired TTP patients by overriding inhibitory antibodies. J Thromb Haemost (2011) 0.88
Hereditary angioedema (HAE) in children and adolescents--a consensus on therapeutic strategies. Eur J Pediatr (2012) 0.88
Elevated serum levels of IGFBP-2 found in children suffering from acute leukaemia is accompanied by the occurrence of IGFBP-2 mRNA in the tumour clone. Br J Cancer (1998) 0.87
The effects of transdermal estradiol and oral conjugated estrogens on haemostasis variables. Thromb Haemost (1994) 0.87
Long-term treatment with growth hormone decreases plasminogen activator inhibitor-1 and tissue plasminogen activator in growth hormone-deficient adults. Thromb Haemost (1996) 0.87
[Imaging methods in diagnosis of cerebrovascular complications with L-asparaginase therapy]. Klin Padiatr (1994) 0.87
Homocysteine, factor VII and antithrombin III in subjects with different gene dosage for cystathionine beta-synthase. J Inherit Metab Dis (1989) 0.86
In vitro stability of polyether and polycarbonate urethanes. J Biomater Appl (2000) 0.85
Droplet motion in microfluidic networks: Hydrodynamic interactions and pressure-drop measurements. Phys Rev E Stat Nonlin Soft Matter Phys (2009) 0.85
APC resistance and other haemostatic variables during pregnancy and puerperium. Thromb Haemost (1999) 0.85
On-demand vs. prophylactic treatment for severe haemophilia in Norway and Sweden: differences in treatment characteristics and outcome. Haemophilia (2003) 0.84
Plasma homocysteine in venous thromboembolism. Haemostasis (1991) 0.84
Determination of protease-cleaved p-aminobenzoic acid (PABA) in serum after oral administration of N-benzoyl-L-tyrosyl-p-aminobenzoic acid (PABA-peptide) in children. Eur J Pediatr (1981) 0.84
Factor VIII inhibitors in two families with mild haemophilia A: structural analysis of the mutations. Haemostasis (2001) 0.84
A comparative study of three low-molecular weight heparins (LMWH) and unfractionated heparin (UH) in healthy volunteers. Thromb Haemost (1995) 0.84
Prospective open-label study of pharmacokinetics, efficacy and safety of a new 10% liquid intravenous immunoglobulin in patients with hypo- or agammaglobulinemia. Vox Sang (2006) 0.84
Pectin-based injectable biomaterials for bone tissue engineering. Biomacromolecules (2011) 0.83
The acute effect of insulin on tissue plasminogen activator and plasminogen activator inhibitor in man. Thromb Haemost (1991) 0.83
Guar gum improves insulin sensitivity, blood lipids, blood pressure, and fibrinolysis in healthy men. Am J Clin Nutr (1992) 0.82
Prospective study on the influence of disease or treatment on pituitary function in 31 children with acute leukemia and non-Hodgkin's lymphoma. Haematol Blood Transfus (1990) 0.82
Inhibitors in the Swedish population with severe haemophilia A and B: a 20-year survey. Acta Paediatr (2002) 0.82
Conjunctival and transcutaneous oxygen monitoring during resuscitation. Ann Emerg Med (1984) 0.82
Vitamin K-dependent carboxylase: possible role of the substrate "propeptide" as an intracellular recognition site. Proc Natl Acad Sci U S A (1987) 0.82
Influenza B pneumonia with Staphylococcus aureus superinfection associated with parvovirus B19 and concomitant agranulocytosis. Infection (2003) 0.82
Maltose in total parenteral nutrition of rats. J Nutr (1973) 0.82
Variation of anti-Fas antibodies in different lots of intravenous immunoglobulin. Vox Sang (2008) 0.82
Can a droplet break up under flow without elongating? Fragmentation of smectic monodisperse droplets. Phys Rev E Stat Nonlin Soft Matter Phys (2004) 0.82
Treatment of children with haemophilia in Europe: a survey of 20 centres in 16 countries. Haemophilia (2000) 0.81
Microalbuminuria, insulin sensitivity and haemostatic factors in non-diabetic treated hypertensive men. Risk Factor Intervention Study Group. J Intern Med (1995) 0.81
Prevention of deep-vein thrombosis and pulmonary embolism after total hip replacement. Comparison of low-molecular-weight heparin and unfractionated heparin. J Bone Joint Surg Am (1991) 0.80
Treatment of venous thromboembolism in patients with congenital deficiency of antithrombin III. Thromb Haemost (1992) 0.80
Femoral artery wall morphology, hemostatic factors and intermittent claudication: ultrasound study in men at high and low risk for atherosclerotic disease. Haemostasis (1996) 0.80
Effects of desmopressin acetate on platelet aggregation, von Willebrand factor, and blood loss after cardiac surgery with extracorporeal circulation. Circulation (1990) 0.80
Structural properties of polysaccharide-based microcapsules for soft tissue regeneration. J Mater Sci Mater Med (2010) 0.80
Clinical experience with human plasma-derived factor VIIa in patients with hemophilia A and high titer inhibitors. Haemostasis (1989) 0.80
Joint health and functional ability in children with haemophilia who receive intensive replacement therapy. Haemophilia (2011) 0.80
[Serum concentrations of insulin-like growth factors (IGF)-I and IGF-II and IGF binding proteins (IGFBP)-2 and IGFBP-3 in 49 children with ALL, NHL or solid tumors]. Klin Padiatr (1995) 0.80
[First results of the THROMKID study: a quality project for the registration of children und adolescents with hereditary platelet function defects in Germany, Austria, and Switzerland]. Hamostaseologie (2007) 0.80
Metformin and metoprolol CR treatment in non-obese men. J Intern Med (1994) 0.79
Effects of Erwinia-asparaginase on the coagulation system. Eur J Haematol (1995) 0.79
Port-A-Cath usage in children with haemophilia: experience of 53 cases. Acta Paediatr (1998) 0.79
Advances in biomedical applications of pectin gels. Int J Biol Macromol (2012) 0.79
X-linked chronic granulomatous disease (CGD) caused by an intra-exonic splice mutation (CYBB exon 3, c.262G->A) is mimicking juvenile sarcoidosis. Clin Exp Rheumatol (2007) 0.79
Experiences with recombinant factor VIII products: development of inhibitors and immune tolerance therapy. Ann Hematol (1998) 0.78
[Experience with the glycerol lysis test in acid medium in diagnosis of hereditary spherocytosis]. Kinderarztl Prax (1993) 0.78